Every material Form 8-K PMGC Holdings Inc. has filed with the SEC since October 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PMGC Holdings disclosed results of a preclinical study of its EL-32 probiotic candidate combined with semaglutide, alongside two new investor relations agreements. The company said the combination did not show a consistent additive benefit over semaglutide alone, and it plans a follow-on study with a lower semaglutide dose, with an update expected in the first quarter of 2027.
Study found a statistically significant greater lean mass at the highest EL-32 dose, but the finding was not reproduced in the low-dose group and was limited to specific measures.
The combination did not demonstrate a consistent additive metabolic benefit over semaglutide alone; the contract research organization noted semaglutide produced substantial effects on its own.
Consulting Agreement with IR Agency LLC dated November 1, 2026 provides for $300,000 in consideration over a term of up to three months starting November 10, 2026.
Senergy Communications Capital Inc. digital marketing agreement dated November 4, 2026 covers roughly one month for a total of C$185,000, exclusive of taxes.
PMGC Holdings entered an October 30, 2026 subscription agreement to buy US$1,845,000 of secured debentures from Nuclea Energy Canada, which will fund Nuclea's acquisition of Moltex Energy assets. The debentures are non-interest-bearing, with a US$45,000 finance fee withheld as an original issue discount, and the deal is a related party transaction tied to PMGC's managing role in a SPAC sponsor. The subscription is conditional and closing is expected by November 30, 2026, so the deal's outcome remains uncertain.
Subscription for US$1,845,000 of debentures, part of an offering of up to US$9,000,000
Finance fee of US$45,000 withheld at closing; debentures bear no interest
Debentures mature at the earliest of three months from issuance or five business days after termination of the business combination agreement, among other events
Closing expected on or before November 30, 2026; proceeds held in escrow by OceanFirst Bank N.A.
PMGC Holdings Inc., doing business as NorthStrive Holdings, furnished two slide decks on October 28, 2026 under Regulation FD: a general holdings presentation (Exhibit 99.1) and a presentation on its Maritime Defense Technology subsidiary (Exhibit 99.2). The filing contains no financial results, guidance, or transaction terms, and the company states the material is not deemed filed under the Exchange Act.
Exhibit 99.1 is an October 2026 investor presentation covering the company's acquisitions, portfolio, biopharmaceutical subsidiary and SPAC sponsorship.
Exhibit 99.2 is a presentation for NorthStrive Defense Tech LLC on a drone payload system licensed from the Florida State University Research Foundation.
The company says the drone prototype is targeted for completion by June 2027, with milestones from September 1, 2026 to June 1, 2027.
The filing states the furnished information is not deemed filed for purposes of Section 18 of the Exchange Act.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PMGC Holdings Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →